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OBJECTIVE: A double-blind, prospective, randomized, controlled trial was performed to 
examine the effects of thoracic epidural block, intravenous remifentanil and intravenous 
clonidine on the postoperative Th1/ Th2-ratio after lung surgery. This study aims to 
analyze the influence of the intervention on long-term survival and possible predictors. 
METHODS: 60 patients were randomized into three groups to receive either 
remifentanil intravenously (remifentanil-group, n=20), remifentanil and clonidine 
intravenously (clonidine-group, n=20) or ropivacaine epidurally (ropivacaine-group, 
n=20) during lung resection. Six years after the operation of the last patient the days of 
survival of all patients were quantified.  
RESULTS: Neither a difference nor an equivalence of the three therapy arms on long-
term survival can be proven, while useful predictors can be identified. 
CONCLUSION: While intraoperative thoracic epidural block decreases the IFN-γ/ IL-4 
ratio immediately after lung surgery, an influence of neurogenic blocks on long-term 
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Einfluss selektiver neurogener Blockaden auf das Langzeitüberleben von Patienten, die sich 
einer Lungenresektion unterzogen haben 
Markus Renius 
 
ZIELSETZUNG: Es wurde eine doppelblinde, prospektive, randomisierte, kontrollierte 
Studie durchgeführt, um den Einfluss eines epiduralen Blocks, einer intravenösen 
Remifentanilgabe und einer intravenösen Clonidingabe auf das postoperative Th1/ Th2-
Verhältnis nach einer Lungenresektion zu untersuchen. Diese Arbeit untersucht den 
Einfluss der Intervention auf das Langzeitüberleben und mögliche Prädiktoren. 
METHODEN: Es wurden insgesamt 60 Patienten randomisiert, um während der 
Lungenresektion doppelblind entweder 1) Remifentanil intravenös (Remifentanil-
Gruppe, n=20), oder 2) Remifentanil und Clonidin intravenös (Clonidin-Gruppe, n=20) 
oder 3) Ropivacain epidural (Ropivacain-Gruppe, n=20) zu erhalten. Sechs Jahre nach 
der Operation des letzten Studienpatienten wurden die postoperativ überlebten Tage 
bei allen Patienten registriert.  
ERGEBNISSE: Es konnte weder ein Unterschied noch eine Äquivalenz der 
Therapiearme in Bezug auf das Langzeitüberleben nachgewiesen werden, wohingegen 
nützliche Prädiktoren identifiziert werden konnten. 
SCHLUSSFOLGERUNG: Obwohl der intraoperative epidurale Block das IFN-γ/ IL-4 
direkt nach der Lungenresektion vermindert, konnte ein Einfluss der neurogenen 
Blockaden auf das Langzeitüberleben nicht gezeigt werden. 
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1 Introduction and Background 
1.1 The Patients 
With lung cancer remaining by far the number one cancer-related death worldwide,(1) 
the collective of lung cancer patients is both of particularly relevant size as well as so 
seriously threatened by the late detection, by the overwhelming aggressiveness and 
lethality of their disease, by their comorbidity and by the lung surgery itself, that an 
operation is the best option for less than 20-25%.(2) Typically this collective is 
predominantly male, with a median age of 60-65 years and often suffering from 
systemic morbidity such as cardiovascular disease and chronic lung disease.(3)(4)(5) 
 
Lung cancer is the primary reason for lung surgery, followed by metastases, suspected 
lung cancer and other tumors.(3) Lung surgery introduces risks such as surgical trauma, 
permanent reduction of surface interface, perioperative infections and fistulae, pain, 
delirium, blood loss, cardiac arrhythmia, postoperative nausea and vomiting and the 
need for intensive care or monitoring in an intensive care setting.(5) Additional 
difficulties arise from the overlap of the operation field and the ventilation, which gave 
rise to the technique of one lung ventilation and which in turn adds further burdens such 
as the temporary reduction of the surface area of the interface, clinically relevant right-
to-left shunt, elevated afterload for the right heart due to hypoxic pulmonary 
vasoconstriction and increased complexity of establishing and maintaining a secure 
airway.(6)(7)(8) 
 
Accordingly, investigations are needed to determine the optimal means to support these 
patients during the perioperative period. Therefore, a clinical trial was performed 
between 2006 and 2008 whose primary objective focused on the changes of the 
immunological homeostasis depending on the type of the intraoperative neurogenic 
block.(9) Another objective is the analysis of the outcome in terms of long-term survival 
which will be described in the following. 
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1.2 The Intervention 
There has been a long and ongoing debate about the impact of the anesthetic regime 
on patient outcome. TEB (thoracic epidural block) is considered by many to be the gold 
standard for lung surgery,(10) though this matter is still under discussion.(11) Recently, 
a solid case was made for it in the editorial of Annals of Surgery(11) where the 
implications of the meta-analysis of Pöpping et al. were discussed. This meta-analysis 
favors epidural anesthesia in combination with general anesthesia over general 
anesthesia alone when postoperative morbidity and mortality is considered,(12) but data 
from prospective, randomized trials which measure the impact of different anesthetic 
regimes during lung surgery on long-term survival is lacking. 
 
The anesthetic regime consists primarily of hypnosis, analgesia and muscle relaxation. 
While intraoperative hypnosis within this study was sustained by default through 
intravenous infusion due to the - still disputed - unwanted effects of inhalational 
anesthetics(13)(14) and to a pragmatic approach to reduce exposure of personnel to 
volatiles during the complex management of the airway, several alternatives are 
available for intraoperative analgesia, such as epidural anesthesia (with or without 
epidural administration of opiates or other epidurally applicable drugs) and continuous 
intravenous administration of remifentanil or other opiates, possibly in combination with 
other analgesic drugs and even the combination of both epidural and intravenous 
analgetic drugs, which is the most common among them. Thus the question arises as to 
which kind of analgesia can be proven to be superior to the others, with a seldom 
clinically used, rather experimental variant in form of a combination of continuous 
intravenous remifentanil and an intravenous sympathetic block by intravenous clonidine 
as a further alternative that is being investigated as the third therapy arm in this study. 
 
Epidural anesthesia reduces intraoperatively the need for both additional 
pharmacological muscle relaxation and systemic opioids and also blocks sympathetic 
innervation in a selective portion of the body.(15)(16) It reduces the need for prolonged 
intubation or reintubation while improving lung function and blood oxygenation.(17)(18) 
This offers the benefit of potent postoperative analgesia(19)(18), avoiding the sedative 
effect and the depressing impact on the respiratory system of systemically administered 
opiates, while ensuring painless coughing to clear infectious sputum from the lungs, 
avoiding atelectases and allowing the best ventilatory excursion in the early 
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postoperative period.(20) These advantages are expected to translate to a lower 
perioperative infection rate,(17) lower postoperative pain levels, less chronification of 
pain, less postoperative nausea and vomiting,(12) less complications of other kinds 
(from deep vein thrombosis and pulmonary embolism to transfusion requirements),(21) 
more comfort for the patient and better integration into a fast-track approach with early 
mobilization and a shorter hospital stay,(22) and enhanced functional capacity and 
health-related quality of life in the weeks after the operation.(23) Furthermore, beneficial 
effects on inflammation,(9) the electrical conduction system of the heart,(12) 
coagulation,(24) reperfusion,(25) cardiovascular(26)(27)(28), endothelial(29) and 
gastrointestinal function(23)(30) have been shown. 
 
On the other hand, there are contraindications for the placement of an epidural catheter, 
and it has to be considered whether the additional time, personnel expenditure, cost 
and the risk of both frequent(17) and rare complications are justified by the benefits,(12) 
with frequent complications being arterial hypotension, pruritus, urinary retention and 
motor blockade(12), and rare complications being severe nerve damage, severe 
cardiotoxic or neurotoxic effects or allergic reactions. 
 
Another therapeutic option is the paravertebral block, which is valuable in cases where 
contraindications won’t allow TEB, and increasingly data has been gathered that shows 
its superiority in some categories compared to TEB.(31) 
 
Alternative approaches, which can be subsumed under the term non-intubated thoracic 
surgery (NITS) and which have in common that  spontaneous ventilation is maintained, 
include intercostal blocks with or without sedation, epidural anesthesia with or without 
sedation (also known under the term “awake epidural anesthesia” or “awake thoracic 
surgery”) and laryngeal mask with sedation, but in thoracic surgery all of them are still 
primarily used in less complex and less invasive surgical procedures(32) or in high-risk 
patients who are not eligible for other anesthetic techniques.(33) Further variants or 
additions with or without the corresponding catheter include intrathecal analgesia, 
intrapleural instillation of local anesthetics, intercostal blocks (non-paravertebral), local 
infiltration, systemic local anesthetics and cryoanalgesia.(34)(35)(36) 
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The concept of neurogenic blocks which can be used for the understanding of the 
function of both regional anesthesia and systemic analgesic agents broadens the 
concept of analgesia and includes afferent and efferent activity, immunological reflexes 
and modulation of the vegetative nerve system.(37) 
 
1.3 The Outcome 
It has already been shown that intraoperatively epidural anesthesia causes a 
significantly altered perioperative immune response (which normally consists of an initial 
hyperinflammation and a consequential overcompensatory response) when compared 
to remifentanil and the combination of remifentanil and clonidine.(9) Now the answer 
should be answered if this translates into a difference in survival as well.  
 
Of all the possible endpoints that are of medical interest when therapies are compared 
(such as length of stay, quality of life, perioperative infections, rate of revision and 
patient's contentment), a strong emphasis is on long-term survival. Besides the 
economic cost and immediate postoperative medical condition and surrogate 
parameters, the years that someone lives after an intervention are of primary 
importance. This is also reflected by the fact that long-term survival was the most 
favored topic of the scientific community when the initial results of the clinical trial were 
presented at various conventions. 
 
Among various survival rates of long-term survival, five years is both the most common 
as well as the most adequate one because five-year survival in lung cancer patients 
ranges from 7%-21% according to the region surveyed,(38) with the corresponding 
survival rate of patients with NSCLC (non-small-cell lung cancer) who undergo complete 
surgical resection being only 40-50%.(2)
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2 The Goal of the Study 
The primary goal of this study is to find out: 
What effect in adult patients without severe cardiovascular or any immunological 
disease who undergo any thoracoscopic or open lung resection does analgesia in lung 
resection in the form of epidural ropivacaine in comparison to intravenous remifentanil in 
comparison to intravenous remifentanil in combination with intravenous clonidine have 
on long-term survival?(39) 
 
The secondary goal of this study is to find out: 
Which predictors for long-term survival can be measured in adult patients without 
severe cardiovascular or any immunological disease who undergo any thoracoscopic or 
open lung resection?(39) 
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3 Materials and Methods 
Major parts of the materials and methods of this study are already published in a 
publication that describes other aspects of the clinical trial.(9) In the following, these 
major parts are complemented with the description of all materials and methods 
involved in the testing of the hypotheses of the present study. In order to honor the 
copyright of the publishing journal, already published sections are in quotations with 
minor changes only for better wording where appropriate or changes in the numbering 
of tables and graphs. 
 
3.1 Approval by the Ethics Committee 
“This double-blinded, prospective, randomized, controlled trial was registered in the 
European Union Drug Regulating Authorities Clinical Trials database (EudraCT 2005-
001456-20) and in the International Standard Randomised Controlled Trial Number 
register (ISRCTN 47414487). The study was approved by the local ethics committee 
“Ethik-Kommission des Landes Berlin” (registration No. EA 1/175/05) and the German 
Federal Institute for Drugs and Medical Devices “Bundesinstitut für Arzneimittel und 
Medizinprodukte, Bonn” (BfArM-No 4030867). Quality of randomization and double-
blinded procedure as well as good clinical practice (GCP) conformity was supervised by 
the contract research organization (CRO) Koordinierungszentrum Klinische Studien 
Charité (KKS Charité).”(9) 
 
A second approval by the ethics committee of the Charité - University Medicine Berlin 
was obtained in order to measure the long-term survival of the study patients (EA1 
287/15). 
 
3.2 Patient Recruitment 
“Consecutive patients scheduled for elective lung surgery at the Charité Campus Mitte 
Hospital, Charité - University Medicine Berlin were screened for eligibility with the goal 
of recruiting 60 patients. According to the clinical trial protocol, patients meeting at least 
one of the following exclusion criteria were not admitted to this study: 1) age under 18 
years, 2) guardianship/ conservatorship, 3) refusal to participate in the study, 4) pre-
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existing changes of the immune system such as infections meeting the criteria of the 
CDC (Centers for Disease Control and Prevention) and/ or treatments and disorders 
with direct influence on the immune system such as immune modulating therapy or 
adrenal pathology, 5) pregnancy, 6) contraindications for epidural catheter insertion, 7) 
contraindications for the application of clonidine, ropivacaine or remifentanil, 8) pre-
existing treatment with the above-mentioned trial drugs or drugs belonging to the same 
pharmacological group within a month prior to the operation, 9) heart failure class III or 
higher according to the NYHA (New York Heart Association) Functional Classification, 
10) myocardial infarction in the last eight weeks before surgery. 
Written informed consent was obtained from all participants.”(9) 
 
3.3 Surgical and Anesthetic Procedures 
3.3.1 Lung Cancer as the Main Indication for Lung Surgery 
Lung cancer is one of the most common and also one of the most serious cancers. It is 
one of the most prevalent causes of death and the most common cause of death among 
cancer deaths worldwide. Its incidence is rising with an estimated 1.8 million lung 
cancer cases in 2012.(1) It is caused to a large degree by human made pathogenic 
substances, mainly active and passive smoking of cigarettes and emissions from 
industry (including occupational exposure), transportation, agriculture, heating and 
cooking, which are two groups of factors which have been reduced in some regions of 
the world, while they are a growing problem in others.(1) Changes in these two areas 
that take place outside of the medical system are more effective than any known 
changes in medical prevention, diagnosis and treatment of the disease, including 
smoking-cessation interventions, which fail to show an effect on cessation rates.(40) 
Other factors include a family history of cancer, an unhealthy diet, male gender, lower 
education level, exposure to radon and chronic obstructive pulmonary disease. 
 
The different entities of lung cancers are grouped based on their histology into types of 
SCLC (small-cell lung cancer), NSCLC and other lung tumors such as other primary 
tumors of the lung (pulmonary carcinoid tumors, pleuropulmonary blastoma, 
neuroendocrine tumors, glandular tumors, lymphomas, sarcomas, vascular tumors of 
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the lung, undifferentiated tumors or combinations thereof), lung metastases of other 
cancers or invasive mediastinal or pleural cancers. The group of NSCLC can further be 
divided into adenocarcinoma, squamous-cell carcinoma and large-cell carcinoma. 
 
The stage of a lung cancer refers to the extent to which the cancer has spread from its 
original source to the rest of the body. Staging is a way to estimate a prognosis and 
decide whether curative or palliative therapy is indicated. It is performed using the TNM 
classification (Tumor - Nodes - Metastases), evaluating the size and localization of the 
primary tumor, the metastases in regional lymph nodes and distant metastases. 
Individual staging is subject to change, as preoperative imaging studies don’t have the 
same reliability as the surgical examination of the intraoperative situs and the intra- or 
postoperative histological analysis that is performed by the pathologist. 
 
Treatments of lung cancer include surgery, radiation therapy and chemotherapy, 
including targeted therapies and combinations thereof. More experimental strategies 
like immunotherapy and epigenetic therapies are being researched or in the process of 
approval.(41)(42) 
 
Lung cancer is known for its bad prognosis, as the illness tends to be diagnosed at a 
late stage, making a cure unlikely. The typical symptoms such as coughing, chest pain, 
weight loss, fever, fatigue, dyspnea, nerve damage and paraneoplastic phenomena are 
both late and/ or too unspecific to allow for timely therapy, making incidental findings the 
most promising cases. Once lung cancer is presumed, chest x-rays, computer 
tomography and/ or positron emission tomography are used to substantiate and a 
biopsy to confirm the presumptive diagnosis. The window of opportunity for a cure is 
primarily not closed due to the size of the tumor or its destruction of vitally important 
lung tissue but by its formation of metastases in the brain, bone, adrenal glands, other 
lung tissue of the ipsilateral or contralateral lung, liver, pericardium and kidneys. 
Possible strategies for the future are therefore the much debated low-dose CT scans 
(X-ray computer tomography) for high-risk individuals as well as the more promising 
development of biomarkers for early detection of lung cancer.(43)(44)  
 
Lung cancer is the most common indication for lung resection. Therefore, any study that 
investigates possible improvement of perioperative care of patients who undergo lung 
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resection also deals with the question whether the therapy of this very common cause 
of death can be improved. 
 
3.3.2 Methods of Lung Surgery 
Several approaches to resecting lung tissue are possible, with VATS (video-assisted 
thoracoscopic surgery) and thoracotomy as the two main techniques. VATS can be 
scaled up to a thoracotomy or a minimal thoracotomy, where the surgical incision in the 
chest wall is shorter than a surgical incision of a conventional thoracotomy, as it only 
serves to enable one specific step of the operation such as the salvage of the resected 
tissue and no other steps such as orientation within the thorax or resection of the tissue. 
While a conventional thoracotomy results in a large trauma (both in soft tissue and ribs) 
accompanied by higher intraoperative and postoperative pain levels, higher stress 
levels with consequential stronger proinflammatory stimulation and antiinflammatory 
counteregulation, a VATS produces very small wounds, with a minimal thoracotomy in 
between the two procedures. A thoracotomy can result in breaking one or more ribs due 
to the surgical procedure of prying open the chest, possibly aggrevated by coughing by 
the patient, which can be caused by insufficient anesthesia. Broken ribs, tissue trauma 
and postoperative pain can result in an involuntary inhibition of the patient to cough in 
the postoperative period, which can cause atelectasis, retention of sputum and 
consequential pneumonia. 
 
3.3.3 Anesthesia for Lung Surgery 
The purpose of Anesthesia in lung surgery is to immobilize the patient, enabling the 
surgeon to reach the intraoperative site with minimal spatial restrictions, protect the 
patient from pain, discomfort and awareness and to maintain equilibrium of vital body 
functions. 
 
3.3.3.1 Thoracic Anesthesia and One Lung Ventilation 
Surgery within the pleural cavity makes it necessary to ventilate only one lung while 
using the space which is normally taken up by the other lung (which is collapsed in 
order to provide this space) to gain access to surgical sites (such as structures 
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neighbouring the lung) and/ or to operate on the collapsed lung while protecting the 
ventilated lung from blood, secretion, pathogens and malignant cells of the other side 
that may be transferred via the main bronchi. This procedure is called lung isolation. 
Historically, two concepts have been established to attain this goal, the double lumen 
tube and the bronchial blocker, while a third concept, namely the vacuum chamber, 
forces the surgeon to operate on the lung without its complete collapse and without 
protection of the ventilated lung from transfer of unwanted material. All three concepts 
have advantages and disadvantages. 
 
The double lumen tube allows CPAP (continuous positive airway pressure) ventilation of 
the collapsed lung in case of severe hypoxia and selective suction cleaning in both 
bronchi. It has the disadvantage of a higher risk of injury of the trachea, carina and 
bronchi due to the rigid form of the preformed tube and its mandrin, and this risk 
increases with any movement of the patient, especially when coughing. The difficulty of 
placing the tube is greatly increased in situations where the patient presents a difficult 
airway and/ or if there is an indication to perform a rapid sequence induction. 
Nevertheless, it is possible to try to counteract these problems by using bronchoscopy 
to guide the double lumen tube to its final position once it has passed the larynx. Double 
lumen tubes vary in their sizes and in their orientation; there are left sided and right 
sided versions, with the right sided versions having a Murphy eye that is merged with 
the bronchial cuff which has to be placed on the opening of the bronchus of the right 
upper lobe in order to secure the ventilation of the right upper lobe. If a pneumonectomy 
of the left lung makes it impossible to use a left sided double lumen tube, it is still 
possible to choose a tube with the opposite orientation. 
 
The bronchial blocker has the advantage of being less invasive. It makes it possible to 
isolate individual lobes. On the other hand, it is not possible to use it for 
pneumonectomy, and neither suction nor ventilation is possible in the blocked bronchus. 
Without the possibility of selectively applying suction to the blocked lung, the risk of 
contamination of the opposite lung with blood, secretion, pus or cancer cells is elevated. 
While a double lumen tube allows one lung ventilation even if the tube is placed in the 
wrong bronchus, the bronchial blocker requires proper positioning. 
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The vacuum chamber is a third option to operate on the lung. It was invented and 
introduced into clinical practice by Ferdinand Sauerbruch in 1904. Its operating expense 
and technical difficulties exceed by far those of the other two options and it has little 
practical significance at the moment, even though experiments with negative pressure 
ventilation in general show promising - though disputed - results.(45)(46) 
 
3.3.3.2 Thoracic Anesthesia and Epidural Blocks 
While epidural anesthesia shows many promising effects, ranging from less endothelial 
injury(29), altered antioxidant markers(47) and stabilized levels of plasma nitrite(48) to 
improved postoperative analgesia(20), it is also associated with risks such as 
hypotension, accidental dura puncture with consequential PDPH (post-dural-puncture 
headache), accidental spinal anesthesia with possible total spinal anesthesia, high 
epidural block, epidural hematoma, epidural abscess, other forms of infection, spinal 
injury and other neurological lesions, accidental systemic application of local anesthesia 
due to intravascular malposition with consequential intoxication as well as possible 
damage to the catheter (primarily during insertion) which can lead to catheter fragments 
remaining in the body. 
There are additional practical considerations, such as a mismatch of the blocked 
dermatomes and the surgical wound or a malposition that results in a missing or 
attenuated or one-sided analgesic effect. While allergic reactions to local anesthetics 
used in epidural anesthesia have been described, it must be emphasized that their rate 
of occurrence pales in comparison to other analgesic drugs such as metamizole.(49) As 
with all analgesic agents, the required dose for sufficient analgesia through epidurally 
administered local anesthetics is different in each individual, which makes it necessary 
to adjust the therapy to the patient being treated. 
 
3.4 Study Medication 
All three drugs that serve as intervention in the trial are well known and routinely used in 
the clinical setting. 
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3.4.1 Epidural Block 
Ropivacaine is a local anesthetic drug of the amino amide type which is used for 
epidural anesthesia (including caudal epidural anesthesia and continuous/ intermittent 
application through an epidural catheter, both intra- and postoperatively), spinal 
anesthesia, nerve blocks and infiltration. It has less cardiotoxicity than bupivacaine and 
is usable both as a racemate and the S-enantiomer, the latter being marketed in the 
form of a hydrochloride by Astra Zeneca under the trade name Naropin ©. 
Contraindications include known allergies triggered by a local anesthetic of the amid 
type, intravenous local anesthesia and extensive use in hypovolemic patients. High 
doses of ropivacaine lead to central nervous complications of varying severity (such as 
convulsions) as well as cardiotoxic effects. These symptoms are enhanced in case of 
erroneous intravenous application and may be masked by general anesthesia. Side 
effects have to be separated into several groups: Firstly, there are side effects 
associated with the positioning of the epidural catheter. These include infections, 
accidental intrathecal insertion or hematoma. These side effects affect all three therapy 
arms as every patient in the trial receives an epidural catheter before operation. 
Secondly, there are side effects due to the nerve block, which can lead, via bilateral 
selective thoracic sympathectomy, to hypotension and bradycardia. Thirdly, there are 
side effects which are caused by the drug when it is absorbed, entering other 
compartments of the body. The latter is intensified by high doses and accidental 
intravascular injection, possibly leading to systemic toxicity. Measures that can be taken 
to avoid systemic administration include the test dose after insertion, assessment of and 
communication with the patient, repeated aspiration of the catheter and vigilant ECG 
(electro-cardiography) monitoring. 
 
3.4.2 Central α2-Agonist 
Clonidine acts as a sympatholytic drug through its stimulation of central α2-receptors, a 
mechanism it shares with dexmedetomidine. Its elimination half life is 10-20 hours. It is 
used in agitated patients suffering from alcohol withdrawal, in patients with hypertension 
in combination with other antihypertensive drugs, in a wide variety of off-label 
indications such as in ADHD (attention deficit hyperactivity disorder) and various 
psychiatric and neurological disorders, as a sedative in intensive care, as analgesia, as 
an additive in epidural anesthesia or spinal anesthesia and in the treatment of the 
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restless legs syndrome as well as rosacea. Contraindications include allergies against 
clonidine or any other ingredient of the marketed formulation, dysfunction of the 
electrical generation and conduction system of the heart (such as sinus bradycardia and 
heart blocks), a heart rate under 50 beats per minute, major depression and 
pronounced hypotension. 
 
Furthermore, clonidine should only be administered under thorough medical supervision 
if patients are diagnosed with coronary artery disease, recent myocardial infarction, 
severe heart failure, severe peripheral artery disease, Raynaud’s phenomenon, 
thromboangiitis obliterans, kidney failure, cerebrovascular insufficiency, constipation 
and polyneuropathy. The minimal lethal overdose of clonidine in rhesus macaques has 
been shown to be three orders of magnitude above a common clinical dose for humans. 
 
3.4.3 Opioids 
Remifentanil is a short acting opioid with exceptional controllability due to its rapid 
hydrolysis by nonspecific plasma and tissue esterases. This controllability can be 
maintained even if high doses are administered for hours; on the other hand, rapid 
fading of the analgesic effect makes it necessary to combine it with a prophylaxis 
against hyperalgesia. It is administered solely via continuous intravenous infusion with 
the intention to sedate or anesthetize patients. As a selective µ-opioid receptor agonist, 
it shows a higher potency than alfentanil while generating similar pharmacological 
effects(50). When combined with hypnotic agents it allows a reduction of the latter 
because of synergistic effects. It is marketed in the form of a hydrochloride by Glaxo 
Smith Kline under the trade name Ultiva©. Because it contains glycin, it must not be 
administered into the intrathecal compartment. It should not be given as the only drug to 
induce anesthesia. Contraindications are allergies against remifentanil or any other 
ingredient of the marketed formulation. 
 
3.5 Study Protocol 
“According to the investigational protocol, patients were randomized in three groups to 
receive either remifentanil intravenously (remifentanil group) or remifentanil and 
clonidine intravenously (clonidine group) or ropivacaine epidurally (ropivacaine group) in 
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a double blinded fashion. Independent pharmacists assigned the patients to the 
different groups according to a computer-generated randomization list based on block 
randomization (six patients per block) and supplied trial drugs and placebo in identical-
appearing coded syringes as shown in Table 1. Without exception, all study personnel 
and participants were blinded to treatment assignment for the whole duration of the 






Clonidine Group Ropivacaine 
Group 
10 ml syringe for  
epidural bolus 
application 
10 ml of placebo  10 ml of placebo 10 ml of 
ropivacaine 
0.75% (75 mg) 
10 ml syringe for  
intravenous 
bolus application 
10 ml of placebo 1 ml of clonidine 
(150 µg) diluted 
with 9 ml of normal 
saline 
10 ml of placebo 




10 mg of 
remifentanil 
diluted with 50 ml 
normal saline 
10 mg of 
remifentanil 
diluted with 50 ml 
normal saline 
50 ml of placebo 




50 ml of placebo 
instead of clonidine 
500 µg clonidine 
(3,3 ml) diluted in 
46,7 ml normal 
saline 
50 ml of placebo 
50 ml syringe for  
continuous 
epidural infusion 
50 ml of placebo 50 ml of placebo 50 ml of 
ropivacaine 0.2% 
(2 mg/ ml) 
 
Table 1. Blinding of the study medication 
“Content of the various types of identical-looking coded syringes that were used for 
delivery of remifentanil, clonidine or ropivacaine during lung resection surgery in the 
present study”(9) (permission granted) 
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After oral premedication with 0.1 mg/kgBW (body weight) midazolam, all patients 
received epidural catheterization independently of randomization. After local infiltration 
of 2-5 ml 1% lidocaine, thoracic epidural puncture was performed in the operating room 
using a median approach by the loss of resistance technique at the level of Th4-Th7. 
After 5 cm catheter insertion into the epidural space, an accidental subdural 
catheterization was ruled out by injecting a test dose of 3 ml bupivacaine 0.5%. All lung 
resections were performed by a lung surgery specialist assisted by at least one senior 
surgeon. Lung resection was performed using either a lateral thoracotomy approach or 
VATS depending on the malignancy, size and localization of the lung disease. 
Anesthesia was performed by a team of anesthesiologists under the supervision of a 
specialist with a great deal of experience in thoracic anesthesia and in accordance with 
a standardized protocol.(51) After epidural catheterization, the trial therapy was started. 
Investigational drugs administration was performed as showed in Figure 1. 
Postoperative analgesia was performed with TEB using ropivacaine 0.2% and 0.5 µg/ml 




Figure 1. Intervention 
 “a) Epidural bolus injection of 75 mg ropivacaine 0.75% or placebo; b) Induction of 
anesthesia with 0.1-0.2 mg fentanyl, 1.5-2.5 mg/kgBW propofol and 0.1 mg/kgBW 























































Remifentanil (or placebo) 
0.2-0.4 µg /kgBW/min  
 
Clonidine (or placebo) 
20-100 µg/h  
 
Ropivacaine (or placebo) 



















































































Intravenous bolus injection of 150 µg clonidine or placebo; d) Intravenous bolus 
injection of 0.1 mg/kgBW morphine and epidural infusion of 6-12 ml/h 0.2% ropivacaine 
plus 0.05 µg/ml sufentanil (verum); e) postoperative care at ICU (intensive care unit) or 
PACU (post anesthesia care unit). BS= Blood Sample”(9) (permission granted) 
 
3.6 Measurement of Postoperative Survival Time 
Postoperative survival was measured with an inquiry at the residents’ registration office. 
The inquiry was performed six years after the operation of the last study patient. This 
yielded data on all patients who complied with the legal duty to register their current 
place of residence at the registration office. This data included the date of death in case 
that the person in question had died in the meantime. When data was not available at 
the registration office or the registration offices of other districts, the contact address in 
the electronic medical file at the hospital and the administrations of cemeteries were 
used to establish whether the person is still alive or not. 
 
The data was entered into the database using the already assigned pseudonyms. An 
online time difference calculator was used to produce the number of days between the 
operation (which is not necessarily the day of recruitment) and the date of death, if 
applicable. Results were tested with regard to their plausibility. 
 
This method can be considered to be prospective because the patient collective is 
prospectively randomized and the intention to measure the long-term survival was 
documented a priori before events that were later measured occurred. So while the 
procedure can be described as retrospective analysis of prospective data the relevant 
properties of a randomized controlled trial (being the elimination of selection bias and 
reduction of confounding to random levels) apply, leaving only the fact that the primary 
goal of the present study wasn’t the primary goal of the clinical trial. This results in the 
problem of any secondary goal which is best described by the fact that with enough 
goals examined, one of them inevitably has to reach significance even if the data is 
random. Therefore, caution should be exercised when it comes to the interpretation of 
these findings. On the other hand, the unique opportunity to use a randomized trial to 
answer a multitude of questions should not be missed. 
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3.7 Measurement of Possible Predictors 
Possible predictors such as sex, age, BMI, ASA (American Society of Anesthesiologists 
physical status classification system), FeV1 (forced expiratory volume in one second), 
the approach of the surgery (VATS or thoracotomy), the history of smoking and whether 
a preoperatively known neoplasia was the reason tor the operation were entered into 
the database according to the CRF (case report form), the anesthesia protocol or the 
patient file. These entries were made during the clinical trial. The smoking status 
included pack years, smoking history and present smoking habits, with the last four 
weeks being the relevant time frame. 
 
3.8 Statistical Analysis 
“Descriptive statistics were computed for all study variables. Discrete variables are 
expressed as counts (percentage) and continuous variables as means ± standard 
deviation (SD) or median (25th – 75th percentiles), respectively. Because of the small 
sample sizes, differences between the groups studied in terms of interesting clinical 
parameters were tested by using non-parametric statistical tests (Kruskal-Wallis tests 
and Mann-Whitney-U tests, respectively). Frequencies were tested by the chi-square-
test in contingency tables. In the case of small samples, greater differences in sample 
sizes, large but unbalanced groups, data sets containing ties, or sparse data, tests were 
carried out in an exact version.”(9) 
 
Long-term survival was analyzed with the Kaplan-Meier method (52) and tested for 
differences with log-rank, Breslow and Tarone-Ware test. However, in order for the 
survival analysis to have full applicability, the condition of the proportional hazard must 
be tested. If the proportions of the hazards of the patients in the three therapy arms are 
constant over time, the Grambsch test will not be significant. 
 
Another problem is to predict the distribution of the time to event (death) from a set of 
explanatory variables or risk factors, in other words to investigate the influence of such 
risk factors on survival. Statistical strategies for prediction are similar to those used in 
ordinary regression. However, in survival analysis we deal with a special type of 
nonlinear regression, the Cox proportional hazard regression. There are some caveats 
involved in this proposition. 
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First of all, the precondition of proportional hazard has to be fulfilled also in the case of 
the Cox regression. As mentioned above, the proportional hazard condition can be 
proved by means of the Grambsch test.   
Second, even though the data of risk factors is available and the calculation with several 
covariates possible, the number of covariates must be limited by theoretical 
considerations.(53)(54) 
 
Numerical calculations were performed with IBM SPSS Statistics, Version 22 (Copyright 
IBM Corporation, Armonk, New York, United States) and StatXact 6 , CYTEL Software 
Corp., Cambridge, MA 02139, USA. A value of p<0.05 was considered to be statistically 
significant. All tests should be understood as constituting exploratory data analysis, 








Figure 2. Flow of participants 
“Flow Chart showing the process of selection and randomization to treatment with 
remifentanil, clonidine or ropivacaine of the lung resection surgery patients who were 
included in the study (data presented according to the Consolidated Standards of 
Reporting Trials [CONSORT] guidelines(55). n = Sample size”(9) (permission granted) 
 
“A total of 113 consecutive patients were screened from January 2006 to May 2007 and 
60 patients met the inclusion criteria and were finally randomized into three groups to be 
treated with remifentanil, remifentanil plus clonidine or ropivacaine. According to the 
CONSORT guidelines, the flow of participants is shown in Figure 2. “(9) 
 
4.2 Basic Characteristics of the Study Patients 
“There were no statistically significant differences between the groups in the measured 
demographic characteristics.”(9) 
 







Age, yr 66.5 (50.0-70.5) 66.5 (61.0-73.0) 65.5 (63.0-70.5) 0.79 
BMI, kg/m2 26.3 (21.5-29.7) 27.1 (24.0-30.4) 26.5 (22.1-30.0) 0.65 
Sex (F/M) 7 (35%)/ 13 (65%) 9 (45%)/ 11 (55%) 4 (20%)/ 16 (80%) 0.23 
ASA classification I/ II/ III/ 
IV. No 
0/ 8/ 12/ 0 0/ 11/ 9/ 0 0/ 8/ 12/ 0 0.54 
Current smoking, No. 3 (15%) 9 (45%) 7 (35%) 0.10 
Preoperative FEV1, L 2.45 (1.98-3.33) 2.43 (1.93-2.71) 2.67 (1.53-3.31) 0.82 
Coexisting cardiovascular 
disease, No. 
11 (55%) 14 (70%) 14 (70%) 0.52 
Pre-existing beta-blocker 
therapy, No. 
7 (35%) 5 (25%) 8 (40%) 0,58 
Pre-existing antidiabetic 
therapy, No. 
3 (15%) 4 (20%) 3 (15%) 0.88 
 
Table 2. Demographic and clinical characteristics of the trial groups 
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“Data are presented as median (quartiles 25-75) or numbers (frequency in %). All 
parameters were taken on admission to the hospital. No. = number”(9) (permission 
granted) 
 
4.3 Clinical Characteristics of the Study Patients 
“There were no statistically significant differences between the groups in the measured 
clinical or hemodynamic characteristics. Operating time, heart rate, systolic and diastolic 
blood pressure before and after induction of anesthesia, oxygenation indices under one 
lung ventilation, VATS rates and cancer incidence did not significantly differ between 
the groups (Table 3). 76% of the patients underwent lung resection via the lateral 
thoracotomy approach; the remaining 24% underwent VATS. None of the patients 
developed early-onset pneumonia or any other postoperative infection within the first 
three postoperative days. There were no differences between the groups in any clinical 
endpoint (Table 4). Perioperative pain was assessed using the NRS (numerical rating 











VATS, No. 6 (30%) 5 (25%) 3 (15%) 0.50 
Cancer histologically 
confirmed, No. 
14 (78%) 16 (80%) 17 (85%) 0.65 
Operating time, 
minutes 
142.5 (90.0-236.25) 157.0 (90.0-213.7) 132.0 (80.0-178.7) 0.81 
Oxygenation index 
before OLV 
344.7 (296.4-384.0) 366.6 (309.2-411.6) 365.9 (335.8-400.3) 0.57 
Oxygenation index 
after 20 min of OLV 
175.5 (87.4-260.0) 115.3 (83.5-235.8) 168.0 (118.0-281.0) 0.28 
Oxygenation index at 
lung resection 
258.0 (166.1-319.0) 173.4 (87.6-236.7) 271.2 (119.0-321.0) 0.10 
Heart rate difference, 
BPM 
28.5 (25.0-35.0) 25.0 (20.0-35.7) 25.0 (20.0-30.7) 0.24 
Heart rate before 
induction, BPM 
81.0 (70.5-87.2) 73.5 (65.0-80.0) 70.0 (65.0-81.5) 0.08 
Heart rate at lung 
resection, BPM 
70.0 (64.5-80.0) 63.5 (56.2-77.2) 62.0 (55.0-80.0) 0.39 
Systolic BP before 
induction, mmHg  
132.5 (128.5-158.7) 130.0 (122.0-153.7) 130.0 (120.0-145.7) 0.53 
Diastolic BP before 
induction, mmHg 
75.0 (70.0-80.0) 75.5 (62.2-80.0) 72.5 (61.2-80.0) 0.55 
Systolic BP at lung 
resection, mmHg 
110.0 (100.7-127.5) 115.0 (96.2-130.0) 110.0 (103.0-115.0) 0.73 
Diastolic BP at lung 
resection, mmHg 
62.0 (60.0-70.0) 60.0 (50.0-70.0) 65.0 (57.0-70.0) 0.39 
 
Table 3. Clinical characteristics and hemodynamic parameters 
“Data presented as median (25 - 75% quartiles) or n or n (%). 
No statistically significant between-group differences (P > 0.05; Kruskal–Wallis test or 
χ2-test). 
Heart rate difference was assessed as the difference between maximum and minimum 
heart rate. OLV = One lung ventilation; min = Minutes; BPM = Beats per minute; BP = 













Pneumonia, No. 0 0 0 - 
Pneumothorax, No. 12 (60%) 10 (50%) 11 (55%) 0.95 
Resurgery, No. 2 (10%) 1 (5%) 1 (5%) 0.77 
Transfused patients, No. 3 (15%) 3 (15%) 1 (5%) 0.47 
Patients admitted to ICU, No. 12 (60%) 13 (65%) 13 (65%) 0.94 
ICU stay, d 1.0 (0.0-1.0) 1.0 (0.0-1.0) 1.0 (0.0-1.7) 0.97 
Readmission to ICU, No. 2 (10%) 2 (10%) 1 (5%) 0.78 
Hospital stay, d 9.0 (5.0-10.7) 7.0 (5.0-12.0) 9.0 (5.0-12.7) 0.81 
Death, No. 0 0 0 - 
 
Table 4. Clinical outcomes 
“Data presented as median (25 - 75% quartiles) or n (%). 
No statistically significant between-group differences (P > 0.05; χ2-test). d = Days”(9) 
(permission granted) 
 
4.4 The Intervention and Long-Term Survival 
The return of the measurement of postoperative survival time was exceptionally high 
with no missing values. The measurement of the data was very precise with every data 
point being narrowed down to the day of death. It was therefore not necessary to censor 
any data within the period under consideration. Censoring is usually necessary due to 
the fact that no information about the event is available, and it weakens the validity of 
the statistical model because assumptions have to be made about all time spans 
between censoring and the end of the investigated period. For statistical analysis, all 
surviving patients were censored at the end of the analyzed period, i.e. survival times of 
patients who are still alive are termed censored survival times. 
 
The statistical analysis was conducted per protocol because the majority of patients 
who were excluded didn’t receive any study medication while the reasons for exclusion 
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do not make a bias through exclusion plausible and because neither crossover nor 
compliance was an issue. 
 
Because of the overall survival rate of 63.3%, the median of overall survival can only lie 
after the end of the observation period, and therefore it cannot be calculated. The same 




Figure 3. Kaplan-Meier curve 
 
The graph of the Kaplan-Meier estimate is shown in Figure 3. The five-year survival 
rates (with standard error) in the three groups were 65%  10.7% for ropivacaine vs. 
60%  11.0% for remifentanil vs. 65%  10.7% for remifentanil plus clonidine, favoring 
no therapy over the other. Accordingly, the test statistic for the Log-Rank test is 0.154 
(p=0.926), for the Breslow test 0.161 (p=0.923) and for the Tarone-Ware test 0.158 
(p=0.924). 
 
With the Grambsch test being significant in this case (p=0.041), the condition of 
proportional hazard is not fulfilled.(56) Therefore, the test results have to be regarded 
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with caution, even though the test statistics besides the Log-Rank test (Breslow and 
Tarone-Ware) are robust against violations of proportional hazard and show similar 
results. 
 
A power analysis (see Table 5) was performed for the Log-Rank test in the given 
situation which yielded a power of 5%. In order to reach a power of 80%, 1499 patients 
per therapy arm would be needed.  
 
 Power needed Power reached 
  Test significance level,  0,050 0,050 
  1 or 2 sided test? 2 2 
      Group 1 proportion 1 at time t 0,450 0,450 
      Group 2 proportion 2 at time t 0,500 0,500 
  Hazard ratio, h=ln( 1) / ln( 2) 1,152 1,152 
  Power ( % ) 80 5 
  n per group 1499 20 
  Total number of events required, E 1568 21 
 
Table 5. Log-rank test of survival in two groups followed for fixed time, constant hazard 
ratio 
 
In order to test whether the survival rates (proportions) in the three groups are 
equivalent, a test of equivalence was performed.(57) 
 
The difference of proportions between the groups (when the groups with no difference 
of proportions, namely ropivacaine vs. remifentanil and clonidine were chosen) was 
tested with specified confidence bounds of -0.2 and 0.2, respectively (wider confidence 
bounds would not be reasonable). The observed confidence bounds of -0.29 and 0.29, 
respectively, exceeded the specified confidence bounds, not rejecting the null 
hypothesis of non-equivalence. The one-sided p-value to reject non-equivalence is 
0.139, also resulting in no rejection of the null hypothesis. 
 
When the confidence bounds were chosen to be narrower with -0.1 and 0.1, 
respectively, the one-sided p-value to reject non-equivalence increased to 0.321. 
When the groups with a difference of proportions were tested (namely remifentanil vs. 
ropivacaine or alternatively remifentanil and clonidine vs. ropivacaine) with specified 
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confidence bounds of -0.2 and 0.2, respectively, the lower observed confidence bound 
rose to -0.341 (compared to -0.29 before). The one-sided p-value to reject non-
equivalence was 0.220 (compared to 0.139 before). When the confidence bounds were 
chosen to be narrower with -0.1 and 0.1, respectively, the one-sided p-value to reject 
non-equivalence further increased to 0.439. 
 
A second power analysis, this time to determine the number of patients needed in order 
to prove equivalence of groups instead of a difference between groups, was performed 
which yielded a power of 35% for an equivalence limit of 0.2 (15% for an equivalence 
limit of 0.1, respectively) when the standard proportion ( S) of 0.45 or 0.50 and a test 
significance level  (one-sided) of 0.05 was chosen. A reduction of the test significance 
level  (one-sided) to 0.025 reduced the power to 24% (and to 9%, respectively). 
 
In order to reach a power of 80%, at least 77 patients per therapy arm would be needed 
for an equivalence limit of 0.2. This number increases with a narrower equivalence limit 
of 0.1 (307 patients per therapy arm), with a reduction of the test significance level  to 
0.025 (98 patients per therapy arm) or with both a narrower equivalence limit and a 
reduced test level (389 patients per therapy arm). These numbers are calculated for the 
standard proportion S being 0.45, with a diminutive change for a S being 0.50. 
The test of equivalence refers only to the proportions of deaths at the end of the 
observation period, not to the chronological sequence of the patient’s deaths. Therefore, 
the condition of proportional hazard does not have to be fulfilled for the test of 
equivalence. 
 
4.5 The Predictors and Long-Term Survival 
The factors that were measured as possible predictors had few missing values. Due to 
the univariate analysis any missing values of one factor didn’t compromise the analysis 
of any other factors. The results are shown in Table 6. As previously mentioned, the 
Cox regression is connected with some requirements: First of all, the precondition of 
proportional hazard, which is not fulfilled. Therefore, results have to be regarded with 
reasonable caution. Secondly the number of influencing factors has to be limited, 
leading to altogether two covariates with 28 events in our case). Nevertheless, these 
results are shown in Table 7.
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Predictor Reference Hazard 
Ratio 
95% CI P Value n 
Sex Male vs. female 0.666 0.285 - 1.559 0.349 60 
Age Per additional year 1.058 1.005 - 1.115 0.033 60 
BMI Per additional unit 1.026 0.932 - 1.130 0.598 59 
ASA III vs. II 2.514 0.983 - 6.433 0.054 60 
VATS Open vs. VATS 0.590 0.240 - 1.450 0.251 60 
Smoking History vs. no history 1.261 0.427 - 3.726 0.675 60 
FeV1 Per additional liter 0.681 0.405 - 1.143 0.146 53 
Cancer Cancer vs. no cancer 1.998 0.465 - 8.585 0.352 56 
 
Table 6. Predictors with their hazard ratios, calculated with univariate Cox regression. 
 
Predictor Reference Hazard 
Ratio 
95% CI P Value n 
Sex Male vs. female 0.648 0.269 - 1.562 0.334 60 
Age Per additional year 1.060 1.006 - 1.116 0.028 60 
BMI Per additional unit 1.031 0.935 - 1.137 0.543 59 
ASA III vs. II 2.585 0.993 - 6.729 0.052 60 
VATS Open vs. VATS 0.600 0.241 - 1.494 0.273 60 
Smoking History vs. no history 1.314 0.438 - 3.938 0.626 60 
FeV1 Per additional liter 0.639 0.373 - 1.095 0.103 53 
Cancer Cancer vs. no cancer 2.053 0.475 - 8.864 0.335 56 
 
Table 7. Predictors with their hazard ratios, calculated with bivariate Cox regression in 
order to adjust for the intervention group. 
 
Because of the borderline p-value of around 0.05 for ASA, its large clinical effect, its 
practical applicability as a risk factor and its routine use, an additional Kaplan-Meier 
curve of the two ASA groups is shown in Figure 4. 
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Figure 4. Kaplan-Meier curve: ASA as a predictor of long-term survival 
 
Despite of the permitted number of only two covariates, we included - though with 
critical assessment by the reader in mind – more covariates into the Cox regression 
showing enlarged p-values for the three most promising predictors (age 0.033 → 0.215; 
ASA 0.054 → 0.278; FeV1 0.146 → 0.560) with hazard ratios tending to 1 (age 1.058 → 
1.040; ASA 2.514 → 1.720; FeV1 0.681 → 0.846). Similar results can be calculated 
without the therapy arm as a covariate with the following p-values (age 0.028 enlarged 
to 0.233; ASA 0.052 enlarged to 0.463; FeV1 0.103 enlarged to 0.442) and hazard 
ratios (age 1.060 → 1.039 ; ASA 2.585 → 1.472; FeV1 0.639 → 0.789). 
One reason for this is the correlation between the predictors, which is highly significant 
between age and FeV1 (p = 0.001), significant between age and ASA (p = 0.021) and 
not significant between ASA and FeV1 (p = 0.109) with the correlation coefficients being 
0.439 for age ~ FeV1, 0.265 for age ~ ASA and 0.172 for ASA ~ FeV1 (calculated with 
Spearman-Rho, one-sided). 
When the observation period is changed, the estimates and the p-values of the three 
most promising predictors change as well (Table 8). 
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 365 (d) 730 (d) 1096 (d) 1461 (d) 1826 (d) 2192 (d) 
Age estimate of risk 1.172 1.069 1.069 1.054 1.058 1.043 
Age p-value 0.011 0.039 0.033 0.048 0.033 0.048 
ASA estimate of risk 2.945 2.162 2.263 2.332 2.514 3.116 
ASA p-value 0.178 0.148 0.103 0.080 0.054 0.010 
FeV1 estimate of risk 0.852 0.637 0.663 0.681 0.681 0.568 
FeV1 p-value 0.685 0.138 0.158 0.146 0.146 0.021 
 
Table 8. Age, ASA and Fev1 as predictors in the context of various lengths of 
observation periods (univariate Cox regression with the previously described references 




5.1 Postoperative Survival Time 
In adult patients without severe cardiovascular or any immunological disease who 
undergo any thoracoscopic or open lung resection, the analgesia during lung resection 
in the form of epidural ropivacaine in comparison to intravenous remifentanil in 
comparison to intravenous remifentanil in combination with intravenous clonidine does 
not have an effect on long-term survival which is measurable in small sample sizes. 
 
5.1.1 Comparison with Other Studies 
In order to compare the results with those of other studies, a literature search with 
PubMed using the key words “epidural survival lung surgery” was performed in June of 
2015. It showed no other study which aimed to determine the influence of intraoperative 
epidural anesthesia on long-term survival in patients who undergo lung surgery. 
However, a wide range of studies investigated similar or related questions, even though 
the randomized controlled trials are clearly in the minority. The exact search syntax 
reads as follows: 
 
epidural[All Fields] AND ("mortality"[Subheading] OR "mortality"[All Fields] OR 
"survival"[All Fields] OR "survival"[MeSH Terms]) AND ("pulmonary surgical 
procedures"[MeSH Terms] OR ("pulmonary"[All Fields] AND "surgical"[All Fields] AND 
"procedures"[All Fields]) OR "pulmonary surgical procedures"[All Fields] OR ("lung"[All 
Fields] AND "surgery"[All Fields]) OR "lung surgery"[All Fields]) 
 
Altogether PubMed showed 203 items. Out of those, 63 items were at least in some 
way linked to the topic of this study. Out of those, 29 items were relevant enough to 
compare them with the present study in terms of study design, type of patients, 
intervention, outcome and number of patients. An overview of those 29 items is shown 
in Table 9. Out of those 29 items, a few studies which display similarities to the present 
study or which reveal other noteworthy contributions to the associated topics are 
described in the following. 
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No. Author Patients Intervention Outcome Study Design n 





















GA vs GA+EA vs 
GA+SPA 
myocardial 





4 Muehling B infrarenal aneurysm repair GA vs GA+EA/ fast track mb, mt, LOS, ILOS R  101 
5 Licker M L: pneumonectomy GA vs GA+EA respiratory comp  retros. multicen. 193 
6 Powell ES L: pneumonectomy EA vs paravertebral block major comp  prosp. multicen. 312 
7 Lehman JF colon surgery SA vs EA LOS, peristalsis  retros. 102 
8 Ammar AD abdominal aortic surgery PCA vs PCEA comp  retros. monocen. 80 
9 
 
Major CP jr. 
 
abdominal aortic surgery 
 








10 Bauer C. L: lobectomy GA vs GA+EA lung function, pain R  68 





rib fractures, elderly 
 








13 Lawrence VA noncardiothoracic surgery  - pulmonary comp  review  
14 Licker M abdominal aortic surgery SA vs EA vs ITM extubation, mb, mt  retros. 595 
15 Palermo S L: lung surgery SA vs EA analgesic effect R  50 







GA vs EA 
 











L: lung surgery 
 










van Lier F 
 
major abdominal surgery 
(with COPD) 












L: lobectomy/ wedge 
resection 
GA vs GA+EA/ fast track 
 
























L: lung surgery 
 








24 Wu CL L: segmental excision SA vs EA mb, mt  retros. cohort 3501 






aortic valve implantation 
EA vs ICC 
 










abdominal aortic aneurysm 
(endovascular) 













L: lung resection (cancer) 
 








Table 9. Results of the literature research 
 
L: = lung surgery; CABG = coronary artery bypass graft; EA = epidural analgesia; GA = general 
anesthesia; SPA = spinal anesthesia; SA = systemic analgesia; PCA = patient-controlled analgesia; 
PCEA = patient-controlled epidural analgesia; ITM = intrathecal morphine; ICC = intercostal catheter; 
comp = complication; mt = mortality; mb = morbidity; LOS = length of stay; ILOS = length of stay in 
intensive care; R = randomized controlled trial; prosp. = prospective; retros. = retrospective; multicen. = 
multicenter; monocen. = monocenter; ITT = intention-to-treat analysis 
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Altogether, only six of the 29 items are randomized trials, which illustrates the general 
deficit of relevant data about the topic. 12 items specifically examine patients who 
undergo lung surgery, but only three of those are randomized trials, with the other three 
randomized trials examining patients who undergo surgery of the circulatory system. 
Out of the studies among the 29 items only eight compare general anesthesia with 
general anesthesia in combination with epidural anesthesia. At least 18 studies defined 
mortality (with any observation period) as one of the outcomes, with a strong emphasis 
on 30-day mortality. 
 
Muehling et al. describes a prospective randomized trial that compares general 
anesthesia with general anesthesia in combination with epidural anesthesia (as part of a 
fast track recovery program), but does so examining patients who undergo elective 
open infrarenal aneurysm repair.(58) The fast track regime includes the lack of bowel 
preparation, reduced preoperative fasting, patient-controlled epidural anesthesia, 
enhanced postoperative feeding and postoperative mobilization. It was not feasible to 
blind; in order to reduce the resultant bias, objective criteria of patient management 
were set. The trial aimed at morbidity, mortality (30d), length of stay in the intensive 
care unit, length of stay and the need for postoperative mechanical ventilation. No 
deaths occurred during the observation period, and while the number of patients with 
medical complications was significantly lower in the fast track group, this is due to the 
difference in functional bowel obstruction, which is both a consequence of the 
sympatholysis and opiate reduction through the epidural block as well as the other 
interventions of the fast track regime that also improve bowel function. 
 
Bauer et al. and Palermo et al. both conducted randomized trials with patients 
undergoing lung surgery, and while the epidural block was tested as intervention, 
mortality wasn’t among the outcomes. In the study of Bauer et al. patients of the control 
group received no epidural anesthesia during or after surgery, which resulted in an 
enhanced pulmonary function and better pain relief in the intervention group. Even 
though it was not the aim of the study, the in-hospital mortality was described to be not 
significantly different between the groups.(59) In the study of Palermo et al. the 
difference between intervention and control groups consisted only in the postoperative 
analgesia, showing a higher efficacy of the epidural anesthesia.(60) 
 
 38 
Powell ES et al. undertook a multicentre, prospective, observational cohort study in 
2005 in order to assess the short term risks after pneumonectomy (due to lung cancer), 
listing age, ASA ≥ 3, preoperative diffusing capacity for carbon monoxide and epidural 
anesthesia as the strongest risk factors for major complications.(61)(62) However, the 
validity of these results suffers from limitations of the study design such as the lack of 
randomization or blinding and poorly chosen outcome parameters like “unplanned 
intensive care admissions” and “inotrope usage” instead of infections or organ failures, 
which would be far better to define the occurrence of a major complication. Most of the 
patients (61.1%) received epidural anesthesia while the main alternative was 
paravertebral block (31%), which is often used when there are contraindications for 
epidural anesthesia. Therefore, the study design allows for unequal assessment of ICU 
admissions: A patient who presents with a contraindication for epidural anesthesia (due 
to preexisting diseases) might postoperatively be admitted to the ICU in a planned 
manner, while a healthier patient without any contraindications might postoperatively be 
admitted to the ICU in an unplanned manner, which creates an - entirely formal - “major 
complication” regarding the latter patient even though the health status of the latter 
patient might be better than that of the first patient, and even though both receive 
intensive care. The study has been criticized for further shortcomings, without any 
response from the authors.(63) In any case, it compares different variations of regional 
anesthesia which doesn’t contribute to answer the hypotheses raised in the present 
study.  
 
Epidural anesthesia has been tested with respect to various outcomes in other forms of 
surgery(64)(65)(66). 
 
5.1.2 The Patients 
The patients in this study who had to undergo lung surgery showed the perioperative 
biphasic sequence of initial proinflammation and subsequent anti-inflammatory 
counterregulation. Additionally, a group difference could be shown, “indicating less 
inflammatory stimulation during surgery”.(9) This group difference did not translate into 
a measurable difference in long-term survival. 
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Comparing studies when the patients, the kind of surgery, local mortality rates or 
therapy standards differ can result in a misleading meta-analysis when applicability is 
considered.(67) 
 
5.1.3 The Intervention 
Table 9 shows how different studies examine different applications of epidural 
anesthesia. Some try to find effects only in the intraoperative phase, while others solely 
focus on postoperative recovery. Bauer et al. managed to design a study where 
analgesia differs both intra- and postoperatively without the ethical problem of an 
epidurally placed sham catheter.(59) 
 
In clinical practice, some anesthetists use the epidural catheter from the very beginning 
of the operation (as was the case also in the present study), while others start the 
application of local anesthetics midway through surgery or towards the end of it. So 
applicability and comparability is subject to differences between and among studies and 
clinical standards. 
 
Neurogenic blocks can interfere with a vast array of physiological and pathophysio-
logical processes. While surgical trauma, stress and pain influence the immune system 
and the immune system influences cancer cells, cancer cells themselves also influence 
the immune system, while neurogenic blocks can interfere with all of these 
interdependencies. 
 
Das et al. summed up the knowledge about these effects in his paper “Are we causing 
the recurrence - impact of perioperative period on long-term cancer prognosis: Review 
of current evidence and practice”:(68) 
“Although complex and controversial, morphine seems to exert its tumor promoting 
effects via: 
1. Promotes apoptosis in lymphocytes and macrophages by activation of the enzymes 
involved in apoptotic cell death. 
2. Affects NO release and inhibits cell adhesion. 
3. Decreases the intracellular concentrations of cyclic adenosine monophosphate 
(AMP) 
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4. Inhibits binding of NF-kB. 
5. Increases angiogenesis by activating cyclooxygenase(COX)-2, reciprocal 
transactivation of VEGF receptors, and production of prostaglandin (PG)-E2. 
6. Stimulates tumor cell migration and proliferation in vitro.(69) 
7. Suppresses NK cell cytotoxicity. 
8. Promotes tumor metastasis and invasion by increased secretion of urokinase like 
plasminogen activator.(70)”(68) 
 
Regarding the central α2-agonist clonidine he notes: 
“Certain tumor cell lines express α2 adrenoceptors on their surface. Stimulation of the 
receptor by agonists (clonidine, dexmedetomedine) was shown to stimulate proliferation 
of tumor cells on top of their NK cell modulating activity.”(68) 
 
And the multiple pathways of inhibition of tumor cells that are known to be caused by 
local anesthetics are gathered as follows: 
“The possible mechanisms may be: 
1. Alteration of DNA methylation of cancer cells. 
2. Reactivation of tumor suppressor genes. 
3. Direct cytotoxic effect. 
4. Direct inhibitory effect on the epidermal growth factor (EGF) receptor. 
5. Reduced mesenchymal stem cell proliferation. 
 
Regional anesthesia per se can attenuate cancer recurrence by several mechanisms: 
1. Decreased neuroendocrine stress response of surgery as indicated by the 
suppression of the rise in serum cortisol level. 
2. Reduced need for general anesthesia. 
3. Reduced opioid consumption. 
4. Maintains NK cell, lymphocyte, and monocyte activity. 
5. Perioperative pain management is superior when regional anesthesia is 
performed.“(68) 
 
There is some evidence that local anesthetics can reduce the rate of recurrence in 
melanoma,(71) breast cancer,(72) prostate cancer(73) and tongue cancer,(74) and 
anesthetic techniques are a relevant factor.(75) 
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5.1.4 The Outcome 
The Kapaln Meier graph (Figure 3) shows an informative profile of the postoperative 
years, with a constant die off during the first 700 days, followed by a sudden change to 
a reduced mortality rate which is also constant for another 1100 days, followed by an 
increase in the mortality rate, the nature of which remaining unknown due to the lack of 
further data. There seem to be two phases in the first five postoperative years, and they 
seem to be associated with different hazards. The first two years seem to show a 
proportional hazard and might be an adequate time span for further studies. When one 
compares the results of this study with other publications a lack of randomized 
controlled trials that measure long-term survival is obvious. 
 
Amat-Santos et al. conducted a prospective study of the effect of TEB in comparison 
with ICC on clinical outcomes following transapical transcatheter aortic valve 
implantation.(76) Among the clinical outcomes was one-year mortality. Even though the 
TEB-group had a lower baseline left ventricular ejection fraction, the overall one-year 
mortality rate was higher in the non-TEB-group (31.1%) than in the TEB group (10.8%), 
with p = 0.005. As the trial was not randomized, a propensity score-matched analysis 
was undertaken in order to reduce selection bias, yielding TEB as an independent 
predictor of decreased cumulative late mortality in a multivariate Cox regression.  
 
5.1.5 Limitations 
The lack of postoperative infections or perioperative death is a sign not only of the 
inclusion criteria, but also of the high quality of the medical care of all disciplines 
involved. The literature shows a rather different picture of the scale of morbidity and 
mortality that is accepted in the perioperative period of lung surgery, e.g. the incidence 
of postoperative pulmonary complications being 10% to 37%.(77) The high quality of 
medical care in the present study is both highly desirable for the patient as well as 
undesirable for the measurement of a difference between groups, because morbidity 
and mortality rates are low.(17) 
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While other studies show a 4- to 10-fold increase in the incidence of hypotension when 
epidural local anesthetics were compared to systemic opioids,(11) such an effect was 
absent in the present study (as can be seen from Table 3). 
 
Additionally any study may produce a Hawthorne effect which increases the quality of 
the diagnostics and therapy of study patients.(78) Study patients are generally known to 
have a better outcome when compared to the basic population.(79) In that sense quality 
not only makes for less noise in the data and therefore improved discernability, but also 
for less unwanted complications and therefore reduced discernability. 
 
Another problem that has two facets in a similar way can be identified: The limitation of 
the length of the three therapy arms. On the one hand, it would have been unethical to 
place a sham epidural catheter with the sole purpose of a successful blinding during the 
study, with little or no net benefit for the patient (though it can be argued that epidural 
saline might have an effect,(80) that the patient profits from the placebo effect and that 
study patients generally have better outcomes). On the other hand, a prolonged 
intervention with both an intraoperative as well as postoperative difference in therapy 
might have a more pronounced effect on all parameters that were measured. Here the 
novel approach of Bauer et al. could be promising,(59) but it too has its drawbacks and 
is not feasible for everyone. 
 
One limitation that has already been extensively discussed is the low power of this 
study. A follow-up study with higher numbers of participants could remove any doubt 
whether differences between the groups might be so small that they can only be 
registered by using large numbers of participants. 
 
5.1.6 Statistical Methods 
The results of the statistical tests prove that neither a difference of the risk of dying 
during the five years after lung surgery nor an equivalence of the risk to have died at the 
end of the five year period can be shown with the present study with respect to the three 
therapy arms. The test for equivalence is a hint that this might be the case due to the 
low power of the study, and the power needed to prove equivalence is markedly lower 
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than the one needed to prove a difference. The equivalence of the risk of dying during 
the five years after lung surgery could not be tested as no suitable method is available. 
 
In summary it can be concluded that either the difference is relatively small or that there 
is no real difference. 
 
Additionally one can deduce that the statistically significant immunological modulation 
that differs between the therapy arms does not translate into either a measurable 
difference in infections or long-term survival, at least with the power of this study. 
 
5.1.7 Negative Findings 
Negative results are usually not favoured in the scientific community, as they offer two 
very different interpretations: Either the methods were faulty so that the noise due to 
mistakes blur the difference between two groups or that the methods were sound but 
that there really is no difference between the two groups. The former is useless, as in 
this case no knowledge is gained. The latter is a useful finding, as in this case it shows 
us which hypotheses have already been tested and don't need to be tested again (at 
least not under the same conditions - here method development, study design and 
furthermore the utilization in meta analyses come into play), therefore saving resources 
for the extensive and laborious testing of other, new hypotheses that might produce 
positive test results. 
 
“I have not failed. I’ve just found 10,000 ways that won’t work.” 
Thomas Edison (1847-1931) 
 
The problem with negative results is that they can't be useful if there is no way to 
discern between the two cases outlined above. In the clinical trial, which is the basis of 
this study, the very nuanced differences between the groups regarding the perioperative 
immune modulation as well as the predictors for long-term survival have shown that 
noise due to faulty methods is not the problem, as otherwise noise would have drowned 
out any of the already measured nuanced differences.(9) 
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Unfortunately, a culture of publication bias affects both of the aforementioned possible 
cases of why negative results occur, leading to less publication even of believable - and 
therefore useful - negative results. 
 
In this whole context, the feasibility of large randomized controlled clinical trials itself 
must be questioned.(81)(82) However, not only the statistical problem of a sufficiently 
large sample with correspondent power, but also the rising financial and administrative 
burden of a randomized controlled trial impedes their realization, favoring studies by the 
biased pharmaceutical industry which is far less restricted in its financial and 
administrative means but partial in its profit motive.(83) This is regrettable, and even 
though the scientific community often laments the lack of hard evidence that is provided 
mainly by large and independent randomized controlled trials, the described 
developments are unlikely to be reversed any time soon. 
 
5.1.8 Applicability 
Because of the randomization of the patients and therefore the absence of a selection 
bias, a statistically significant result would prove causality, even though this is limited by 
the fact that the present study is not the primary objective of the clinical trial. The 
statistical proof of a difference would contribute to the growing field of 
oncoanesthesia,(68) while the statistical proof of equivalence would contribute to the 
discussion about the gold standard for lung surgery. This very discussion has been 
substantially affected by the recent meta-analysis on the impact of epidural analgesia 
on mortality and morbidity after surgery by Pöpping et al.(12), which “has shown that the 
preponderance of evidence demonstrates that postoperative epidural analgesia not only 
provides “soft” benefits such as early mobilization and reduction in venous 
thromboembolism but also affords a survival advantage that is meaningful, given the 
large numbers of eligible patients.”(11) 
 
This significance is further specified: 
“The strength of the benefit varied from a statistically significant 40% decrease in odds 
of death to a borderline significant 25%, depending on the studies included, and the 
number needed to treat to prevent a death ranged from about 55 to 250.”(11) 
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Of course the kind of studies that were included have a strong influence on the 
transferability on the present study. But beyond that, the number needed to treat 55 to 
250 patients shows how our study with 60 patients and no death within in the first month 
is underpowered to show a difference in the early postoperative mortality of the therapy 
arms. The first study patient died after 35 days, followed by the time spans of 146 and 
148 days for the second and third study patients. 
 
The problem of detectability of an effect by small studies of high quality is brought up as 
well: 
“Controversy remains regarding the effect of epidural analgesia on mortality, with large 
database studies suggesting a 30-day mortality benefit {[odds ratio (OR) = 0.89; 95% 
confidence interval (CI), 0.81–0.98] and [OR = 0.74; 95% CI, 0.63–0.89]} whereas 
smaller, higher quality randomized controlled trials such as the MASTER trial (N = 915) 
and the Veterans Affairs study (N = 1021) showing no difference, likely because of the 
large sample size needed to detect a mortality difference.”(11) 
 
Nevertheless, the relevance of even small risk reductions is valued accurately: 
“Finally, despite the small absolute risk reduction (ie, 3%–2%), the findings are still 
clinically important because of the very large population of patients to whom the results 
apply.”(11)  
 
The time span for which mortality should be registered is also considered: 
“The majority of benefit was realized in the 30- to 60-day range, a biologically plausible 
outcome due to the cumulative benefits on individual organ morbidity.”(11) 
Here a distinction should be made between various effects: The direct postoperative 
complications with short-term consequences (e.g. pneumonia), the direct postoperative 
complications with long-term consequences (e.g. some thromboembolic events) and the 
complications at a later date with long-term consequences (e.g. cancer recurrence). The 
additional death rate through aging, accidents, the underlying disease and other 
primarily unrelated illnesses can be attenuated as a source of interference through 
randomization, but nevertheless these effects have also to be considered when 
interpreting short-term and long-term postoperative mortality. 
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Summing up it can be said that even though to date no one has aimed at the same goal 
as the present study, the results nevertheless complement the previous state of 
knowledge.  
 
5.2 The Predictors 
The predictor “sex” was not significant after univariate analysis or with correction for the 
intervention. It should be mentioned that women were clearly in the minority and that 
gender-specific differences in smoking habits and other aspects of lifestyle might play a 
role, along with many other factors. 
 
The predictor “age” was significant both after univariate analysis and with correction for 
the intervention, and this is valid not only for the observation period of five years, but for 
any observation period between one and six years. Its ability to predict is even stronger 
in short observation periods, showing the biggest estimated additional risk in 
combination with high significance during the first year. This implies that age is more 
relevant for the prediction of survival after an operation than it is for the general 
prediction of the remaining life expectancy. It shows a lot of overlap with other 
measurable factors, including the other two predictors which are significant after six 
years, namely ASA and FeV1. An aspect in its favor is its effortless measurement. It is 
primarily a formal, not a functional attribute. 
 
The predictor “BMI” was not significant after univariate analysis or with correction for the 
intervention. It is generally a poor concept, as it does not differentiate between different 
tissues (mainly fat tissue, muscle tissue, water and bones) that make up the human 
body. An apt example is the BMI of a bodybuilder which can easily reach values that are 
equal to those of another person that is already limited in his or her movement by 
excessive fat tissue. Therefore, any methods that measure the actual percentage and 
distribution of body fat are more suitable. There is however an exception, because a 
very low BMI shows a lack of tissue, with little range of variation for the remaining 
tissue. Here, much more meaningful findings exist.(84) BMI is also primarily a formal, 
not a functional attribute. 
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The predictor “ASA” was significant both after univariate analysis and with correction for 
the intervention, but only after an observation period of six years, showing only marginal 
significance - and therefore only weak evidence for an effect - after five years. Its ability 
to predict is even weaker in short observation periods, showing smaller estimated 
additional risks - though with no significance - when applied during the first 365, 720, 
1096 or 1461 days. This implies that it is more relevant for the prediction of the 
remaining life expectancy, rather than the prediction of survival after an operation. It 
shows a lot of overlap with other measurable factors, including the other significant 
predictors. An aspect in its favor is its effortless measurement, as it is routinely assigned 
by the assessing anesthetist. An additional advantage is that it is a functional, not a 
formal attribute and that it reduces complexity, expressing the general fitness and health 
status in only one number. It should be noted that the sample consisted exclusively of 
patients with ASA II and III. This is an adequate reflection of the respective population 
as patients with ASA I neither have the typical risk factors such as lung disease and 
nicotine abuse nor do they show serious symptoms which would bring about a detection 
of a lung disease that needs to be operated on. Patients with ASA IV usually won’t have 
the suitable prognosis or physical resources to qualify for a lung operation with one lung 
ventilation. 
 
The predictor “VATS” was not significant after univariate analysis or with correction for 
the intervention. It should be mentioned that VATS were the distinct minority. 
Nevertheless one would expect a pronounced difference due to the summation of many 
factors such as severity of the underlying disease, tumor size, tissue trauma and other 
complications that are associated with open resection. 
 
The predictor “smoking” was not significant after univariate analysis or with correction 
for the intervention. It should be mentioned that patients without a history of smoking 
were the distinct minority. If speculations about causality are made, it is questionable 
whether patients without a history of smoking have the same chance of survival as 
patients with a history of smoking. Rather, all patients without a history of smoking that 
have to undergo lung surgery may be so sick that their chances of survival even 
approach those of the patients with a history of smoking. Another reasoning would be to 
once again make the distinction between formal and functional parameters, with the 
history of smoking being a formal one. 
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The predictor “FeV1” was significant both after univariate analysis and with correction 
for the intervention, but only after an observation period of six years. Its ability to predict 
is weaker in short observation periods, showing smaller estimated additional risks - 
though with no significance - when applied during the first 365, 720, 1096 or 1461 days. 
This implies that it is more relevant for the prediction of the remaining life expectancy, 
rather than the prediction of survival after an operation. In contrast to the other 
predictors, this parameter has seven missing values, making a significant result less 
likely. Nevertheless, the estimated additional risk of death during the six years after 
surgery is reduced to 57% for one additional liter of FeV1 (p-Value = 0.021). It shows a 
lot of overlap with other measurable factors, including the other significant predictors. 
The objective measurement of obstruction requires some effort, but this doesn’t impair 
its role as a practical predictor, as it is routinely performed because of the underlying 
disease or as part of the common preoperative assessment. It is a functional, not a 
formal attribute. 
 
The predictor “cancer” was not significant after univariate analysis or with correction for 
the intervention. The four missing values are unlikely to be the decisive factor for this. It 
should be mentioned that patients without cancer were the distinct minority. 
Nevertheless one would expect a pronounced difference due to the summation of many 
factors which are associated with cancer. But one could argue that patient who have to 
undergo lung surgery suffer from other conditions that are similarly compromising their 
health. And one could consider the fact that lung surgery was considered only as a 
curative option (i.e. no debulking) - probably curing most of the patients through the 
operation and filtering out those severe cases where curative surgery is no longer an 
option. 
 
In summary, there is not enough evidence that those predictors that measure or 
represent function are superior to merely formal ones, but the only exception to this rule 
was age. Being a formal predictor, it shows a 17% elevated additional risk (of death 
within the first postoperative year) for each year of one’s life with a p-value of 0.011. 
 
ASA, FeV1 and age are accessible, reliable and significant predictors of postoperative 
survival, though it is a requirement when using both ASA and FeV1 to choose the right 
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observation period. All three predictors are superior to the other predictors which mostly 
show plausible estimates of additional risk but lack significance. 
 
The published opinion that a predictor should be rejected only because more 
comprehensive or suitable ones could be developed or because they were initially not 
designed to be a predictor is unfounded.(85) 
 
5.3 Conclusion 
While intraoperative thoracic epidural block decreases the IFN-γ/ IL-4 ratio immediately 
after lung surgery, an influence on long-term survival could not be shown. This is most 
likely due to the high NNT (number needed to treat) that has been shown in meta-
analyses, making further randomized controlled trials with higher numbers of patients 
necessary. 
 
Meaningful predictors for reduced long-term survival could be identified, confirming age 








6 Abbreviations  
  test significance level 
ADHD  attention deficit hyperactivity disorder 
AND  Boolean operator 
ASA American Society of Anesthesiologists (physical status classification system) 
BfArM  Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn 
BMI  body mass index 
BP  blood pressure 
BPM  beats per minute 
BS  blood sample 
BW  body weight 
CABG  coronary artery bypass graft 
CDC  Centers for Disease Control and Prevention 
cm  centimeter 
comp  complication 
CONSORT Consolidated Standards of Reporting Trials 
CPAP  continuous positive airway pressure 
CRF  case report form 
CRO  contract research organization 
CT scan  X-ray computed tomography 
d  days 
EA  epidural analgesia 
ECG  electrocardiography 
EudraCT European Union Drug Regulating Authorities Clinical Trials database 
FeV1  forced expiratory volume in one second 
GA  general anesthesia 
GCP  good clinical practice 
h  hour 
ICC  intercostal catheter 
ICU  intensive care unit 
IFN-γ  Interferon gamma 
IL-4  Interleukin 4 
ILOS  length of stay in the intensive care unit 
ISRCTN International Standard Randomised Controlled Trial Number register 
ITM intrathecal morphine 
ITT intention-to-treat analysis 
kg  kilogram 
KKS Charité Koordinierungszentrum Klinische Studien Charité 
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L  liters 
L:  lung surgery 
LOS  length of stay 
mb  morbidity 
µg  microgram 
mg  milligram  
min  minutes 
ml  milliliter 
mmHg  millimeter of mercury 
monocen. monocenter 
mt  mortality 
multicen. multicenter 
n  sample size 
NITS  non-intubated thoracic surgery 
NNT  number needed to treat 
No.  number 
NRS  numerical rating scale 
NSCLC  non-small-cell lung cancer 
NYHA  New York Heart Association 
OLV  one lung ventilation 
OR  Boolean operator 
p  p-value 
PACU  post anesthesia care unit 
PCA  patient-controlled analgesia 
PCEA  patient-controlled epidural anesthesia 
prosp.  prospective 
S  standard proportion 
R  randomized controlled trial 
retros.  retrospective 
SA  systemic analgesia 
SCLC  small-cell lung cancer 
SD  standard deviation 
SPA  spinal anesthesia 
TEB  thoracic epidural block 
Th  thoracic vertebra 
TNM  tumor, nodes, metastases 
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